Condition: MASH - Metabolic Dysfunction-Associated Steatohepatitis · Sponsor: Nabiqasim Industries (Pvt) Ltd
Phase 4 clinical trial study aims to further evaluate the safety and therapeutic efficacy of Resmetirom in Pakistani patients with fibroscan proven MASH.
This description comes directly from the study's public registry record.
Hussain B Abidi, MBBS, MBA, CRCP · +923322583236 · MDR.hussainabidi@gmail.com
Always discuss trial participation with your own doctor first.
| Liver transplant center, Holy family hospital | Rawalpindi, Punjab Province, Pakistan | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07249788